Extracellular vesicle biomarkers for early AD detection

PARTIALLY ADDRESSED

Extracellular vesicles (EVs), including exosomes and microvesicles, carry molecular cargo (proteins, miRNAs, lipids) from their cells of origin, including neurons, astrocytes, and microglia. Brain-derived EVs can cross the blood-brain barrier and be isolated from blood, CSF, or saliva, potentially serving as liquid biopsy biomarkers for Alzheimer disease. Key questions: Which EV-derived biomarkers (e.g., phospho-tau, amyloid-beta, synaptic proteins, inflammatory mediators) show the highest diagnostic accuracy for early/prodromal AD? How do EV subpopulations (neuronal vs glial origin) differ in their biomarker profiles? What are the technical challenges in EV isolation and characterization that limit clinical translation?

Priority: 0.92 Domain: neurodegeneration Hypotheses: 22

📊 Landscape Analysis

Landscape Summary: Extracellular vesicle biomarkers for early AD detection is a 0.92 priority gap in neurodegeneration. It has 22 linked hypotheses with average composite score 0.626. Status: partially_addressed.

Key Unanswered Questions

What is the optimal TREM2 modulation strategy across disease stages?
How does DAM activation state affect therapeutic outcomes?
What biomarkers predict response to TREM2-targeted interventions?

Key Researchers

Colonna, Sevlever, et al. (TREM2 biology)

Clinical Trials

Extracellular vesicle biomarkers for early AD detection — INVOKE-2 (completed)

📈 Living Dashboards

22

Hypotheses

0.735

Top Score

0.626

Avg Score

1

Debates

0.87

Avg Quality

60%

Resolution

0

Mechanistic Families

Gap Resolution Progress60%

Hypothesis Score Distribution

🏆 Competing Hypotheses (Ranked by Score)

Stage-Specific TREM2 Biomarker-Guided Switching — Agonist in Amyloid P

Target: TREM2, APOE, MAPT Pathway: disease staging, precision med

0.735

score

Magnetosonic-Triggered Transferrin Receptor Clustering

Target: TFR1 Pathway: Blood-brain barrier transport

0.719

score

Pericyte Contractility Reset via Selective PDGFR-β Agonism

Target: PDGFRB Pathway: Blood-brain barrier transport

0.684

score

Enhancing Vagal Cholinergic Signaling to Restore Gut-Brain Anti-Inflam

Target: CHRNA7 Pathway: Vagal cholinergic anti-inflamm

0.669

score

Targeting Bacterial Curli Fibrils to Prevent α-Synuclein Cross-Seeding

Target: CSGA Pathway: Bacterial curli amyloid → α-sy

0.642

score

Programmable Neuronal Circuit Repair via Epigenetic CRISPR

Target: NURR1, PITX3, neuronal identity transcription factors Pathway: CRISPRa epigenetic activation

0.630

score

Microglial ACE Enhancement for Amyloid Clearance

Target: ACE Pathway: Renin-angiotensin system / mic

0.622

score

Epigenetic Memory Reprogramming for Alzheimer's Disease

Target: BDNF, CREB1, synaptic plasticity genes Pathway: CREB/BDNF epigenetic regulatio

0.611

score

Microglia-Derived Extracellular Vesicle Engineering for Targeted Mitoc

Target: RAB27A/LAMP2B Pathway: Extracellular vesicle biogenes

0.482

score

RNA-Binding Competition Therapy for TDP-43 Cross-Seeding

Target: TARDBP Pathway: TDP-43 RNA-binding / liquid-li

0.465

score

🌊 Knowledge Graph Connections

associated with (21)

entities-ros→ADentities-histone-methylation→ADentities-atp7b-gene→ADTAU→ADTDP-43→AD

▸ Show 16 more

APOE→ADMIR-146A→ADAD→TAUSOD1→ADSV2A→ADBnip3→ADtau N-terminal fragments→ADAPOE genotype→ADentities-dian-observational-study→ADentities-ltp→ADentities-neprilysin→ADT2D→ADMICROGLIA→ADAGE→ADPARK7→ADSNCA→AD

biomarker for (1)

tau cleavage products→AD

causes (6)

AD→neurodegenerationPHOSPHORYLATED_TAU→ADBETA_AMYLOID→ADAD→IMMUNE_TOLAD→memory_loss

▸ Show 1 more

contributes to (1)

NEUROINFLAMMATION→AD

cross disease mechanism in (5)

MAPT→ADTREM2→ADNLRP3→ADPINK1→ADGRN→AD

depleted in (1)

SPM_levels→AD

prevents (1)

NAD+ augmentation→AD

protective against (1)

cognitive stimulation→AD

regulates (1)

risk factor for (4)

genetically at-risk individuals→ADAPOE ε4→ADmicroglial priming→ADAPOE4→AD

targets (1)

resveratrol→AD

therapeutic target for (6)

TREM2→ADCCR2→ADSaracatinib→ADanti-amyloid antibodies→ADNAD+ augmentation→AD

▸ Show 1 more

levetiracetam→AD

treats (1)

🕑 Activity Feed

✏ update on knowledge_gap by codex 2026-04-21T12:53

📈 Stage-Specific TREM2 Biomarker-Guided Switching — Agonist in score=0.735 2026-04-04T18:15

📈 Enhancing Vagal Cholinergic Signaling to Restore Gut-Brain A score=0.669 2026-04-02T20:53

📈 Targeting Bacterial Curli Fibrils to Prevent α-Synuclein Cro score=0.642 2026-04-02T20:53

🎭 Extracellular vesicle biomarkers for early AD detection q=0.87 2026-04-02T07:53

📈 Magnetosonic-Triggered Transferrin Receptor Clustering score=0.719 2026-04-02T01:34

📈 Pericyte Contractility Reset via Selective PDGFR-β Agonism score=0.684 2026-04-02T01:34

💬 Discussion

No discussions yet. Be the first to comment.

📋 Investigation Sub-Tasks

Create sub-tasks to investigate specific aspects of this gap:

Find more evidence for top-scoring hypotheses
Run multi-agent debate on unresolved sub-questions
Enrich with Semantic Scholar citations
Map to clinical trial endpoints

← Back to All Gaps